Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

ent expenses related to the cessation of the development of Sulonex in March 2008, a $5.4 million decrease in research and development expenses related to KRX-0401 (perifosine), a $20.8 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the Company's significant ongoing obligations included in the original agreement ($18.0 million) and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009, and a $3.6 million increase in other revenue primarily related to the settlement of a dispute for $3.5 million (as discussed above).

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made substantial progress in the third quarter. Following our announcements of an SPA for the Phase 3 trial of perifosine in multiple myeloma, and exciting long-term safety and efficacy data for Zerenex, we solidified our balance sheet with a $20 million registered direct offering." Mr. Bentsur added, "We believe we now have sufficient capital to complete the Phase 3 programs for Perifosine and Zerenex, both of which are nearing commencement."

On Tuesday, November 10, 2009, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief overview of the Company's third quarter financial results and a business outlook for the remainder of 2009.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of m
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
(Date:8/21/2014)... 21, 2014  Zacks.com announces the list of stocks featured ... analysts discuss the latest news and events impacting stocks and ... Hewlett-Packard (NYSE: HPQ - Free Report ), IBM (NYSE: ... SB - Free Report ), GlaxoSmithKline plc (NYSE: ... FI - Free Report ). Today, Zacks ...
(Date:8/21/2014)... , Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health and ... two investor conferences in September: , September 4, ... York , NY at 12:50 p.m. ET , September ... in New York , NY at 1:25 p.m. ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11Henry Schein To Present At Two Investor Conferences In September 2
(Date:8/22/2014)... Texas (PRWEB) August 23, 2014 ... Industry” is a professional and in-depth research report ... basic Glucose Meter information, including Glucose Meter definition, ... as industry overview. This research covers the international ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Today, Zane ... new guide on Account-Based Health Plans. , According to ... as a strategy to lower the cost of healthcare ... of medical spending accounts, however, can be confusing. , ... to learn the four main types of ABHPs. It ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 MyWriters.com ... is written by marketing experts for marketers to help ... has caught the attention of Shane Michaels, prompting an ... Internet marketing in any way knows that content is ... the industry,” reports Michaels. “But even though content is ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Buying a ... an adult who is unsure about available coverage types by ... providing principal life insurance policy pricing to the public using ... use of this tool is free and is expected to ... available to the public throughout the U.S. The system is ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
Breaking Medicine News(10 mins):Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... pulmonary fibrosis often do not get referred to a tertiary ... a higher death rate. Better methods of early ... (NEW YORK, NY, July 1, 2011) Idiopathic pulmonary ... the predominant condition leading to lung transplantation nationwide. Columbia University ...
... have discovered the first of an entirely new class ... development of blood vessels. In a report in ... the investigators describe how a compound derived from a ... to interfere with blood vessel formation in animal models ...
... the American College of Radiology suggests that self-referral ... diagnostic imaging growth. Self-referred imaging is identified as ... to their own on-site imaging services or the referral of ... financial interest. In the current political and ...
... Reporter , THURSDAY, June 30 (HealthDay News) -- Annual low-dose ... 20 percent in heavy smokers and formerly heavy smokers, compared ... results of a major National Cancer Institute study released on ... major advance in efforts to combat lung cancer deaths. By ...
... up and down the court aspiring to NBA stardom. Now, ... to achieving their hoop dreams: sleep. In a study ... Mah, a researcher in the Stanford Sleep Disorders Clinic and ... college level were able to improve their on-the-court performance by ...
... Samuel Waxman Cancer Research Foundation have partnered to establish a ... the two Foundations are proud to announce the award of ... School of Medicine in Atlanta. Van Meir,s research aims to ... the Ewing sarcoma family of tumors (ESFT) oncoprotein. Ewing ...
Cached Medicine News:Health News:Delayed access to tertiary care associated with higher death rate from type of pulmonary fibrosis 2Health News:Mass. General team identifies new class of antiangiogenesis drugs 2Health News:Self-referral: A significant factor in imaging growth 2Health News:Who Should Get a CT Scan to Screen for Lung Cancer? 2Health News:Who Should Get a CT Scan to Screen for Lung Cancer? 3Health News:Who Should Get a CT Scan to Screen for Lung Cancer? 4Health News:Who Should Get a CT Scan to Screen for Lung Cancer? 5Health News:Snooze you win? It's true for achieving hoop dreams, says Stanford study 2Health News:Snooze you win? It's true for achieving hoop dreams, says Stanford study 3Health News:Targeting the Ewing sarcoma family of tumors 2
... a minimum results in less emotional trauma ... the clinician. The innovative motor plus saw ... lighter package. In addition, the unique design ... more user comfort. Plus automated multi-speed controls ...
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws....
LEMAIRE stapes are stainless steel staples indicated for ligament fixation....
... Osteotomies and ligament ... a small number of ... Arthrodesis is the most ... of suitable staples allow ...
Medicine Products: